Adenosine

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Adenosine
Generic name
ADENOSINE
Manufacturer
Fresenius Kabi USA, LLC
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
f88a8cf7-d354-42f2-b5e8-ba002fcfc460
SPL ID
2a538eee-679f-4606-b36f-5fc0fb1c885d
Version
3
Effective date
2023-03-02
Source export date
2026-11-13
Source partition
12
Source file
https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/df974ce21ba33b4471866e2af5412327fbd4bcd68d14b42d7cfb3aa15d163738/drug-label-0012-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 17:51:40
Harmonized routes table
Harmonized routes
INTRAVENOUS

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 2 of 3 · 10 matching rows.

warnings and cautions

5.4 Hypotension Adenosine is a potent peripheral vasodilator and can induce significant hypotension. The risk of serious hypotension may be higher in patients with autonomic dysfunction, hypovolemia, stenotic valvular heart disease, pericarditis or pericardial effusions, or stenotic carotid artery disease with cerebrovascular insufficiency. Discontinue adenosine in any patient who develops persistent or symptomatic hypotension.

warnings and cautions

5.5 Cerebrovascular Accident Hemorrhagic and ischemic cerebrovascular accidents have occurred. Hemodynamic effects of adenosine including hypotension or hypertension can be associated with these adverse reactions [see Warnings and Precautions ( 5.4 ) and ( 5.9 )] .

warnings and cautions

5.6 Seizures New-onset or recurrence of convulsive seizures has occurred following adenosine. Some seizures are prolonged and require emergent anticonvulsive management. Aminophylline may increase the risk of seizures associated with adenosine. Methylxanthine use is not recommended in patients who experience seizures in association with adenosine administration [see Overdosage ( 10 )].

warnings and cautions

5.7 Hypersensitivity, including Anaphylaxis Dyspnea, throat tightness, flushing, erythema, rash, and chest discomfort have occurred. Symptomatic treatment may be required. Have personnel and appropriate treatment available. Resuscitative measures may be necessary if symptoms progress [see Post-Marketing Experience ( 6.2 )].

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 2 · 5 matching rows.

adverse reactions

6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the prescribing information: Fatal Cardiac Arrest, Ventricular Arrhythmias, and Myocardial Infarction [see Warnings and Precautions ( 5.1 )] Sinoatrial and Atrioventricular Nodal Block [see Warnings and Precautions ( 5.2 )] Bronchoconstriction [see Warnings and Precautions ( 5.3 )] Hypotension [see Warnings and Precautions ( 5.4 )] Cerebrovascular Accident [see Warnings and Precautions ( 5.5 )] Seizures [see Warnings and Precautions ( 5.6 )] Hypersensitivity [see Warnings and Precautions ( 5.7 )] Atrial fibrillation [see Warnings and Precautions ( 5.8 )] Hypertension [see Warnings and Precautions ( 5.9 )] Most common adverse reactions (incidence ≥ 10%) are: flushing; chest discomfort; shortness of breath; headache; throat, neck or jaw discomfort; gastrointestinal discomfort; and dizziness ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The following adverse reactions, with an incidence of at least 1%, were reported with adenosine among 1,421 patients in clinical trials. 11% of the adverse reactions occurred several hours after adenosine administration. 8% of the adverse reactions began with adenosine infusion and persisted for up to 24 hours. The most common (incidence ≥ 10%) adverse reactions to adenosine are flushing, chest discomfort, shortness of breath, headache, throat, neck or jaw discomfort, gastrointestinal discomfort, and dizziness (Table 2). Table 2. Adverse Reactions in Clinical Trials (Frequency ≥ 1%) Adverse Reactions Adenosine N=1,421 Flushing 44% Chest discomfort 40% Dyspnea 28% Headache 18% Throat, neck or jaw discomfort 15% Gastrointestinal discomfort 13% Lightheadedness/dizziness 12% Upper extremity discomfort 4% ST segment depression 3% First-degree AV block 3% Second-degree AV block 3% Paresthesia 2% Hypotension 2% Nervousness 2% Arrhythmias 1% Adverse reactions to adenosine of any severity reported in less than 1% of patients include: Body as a Whole: back discomfort, lower extremity discomfort, weakness Cardiovascular System: myocardial infarction, ventricular arrhythmia, third-degree AV block, bradycardia, palpitation, sinus exit block, sinus pause, T-wave changes, hypertension (systolic blood pressure > 200 mm Hg) Respiratory System: cough Central Nervous System: drowsiness, emotional instability, tremors Genital/Urinary System: vaginal pressure, urgency Special Senses: blurred vision, dry mouth, ear discomfort, metallic taste, nasal congestion, scotomas, tongue discomfort 6.2 Post-Marketing Experience The following adverse reactions have been reported from marketing experience with adenosine. Because these reactions are reported voluntarily from a population of uncertain size, are associated with concomitant diseases and multiple drug therapies and surgical procedures, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiac Disorders: cardiac arrest, atrial fibrillation, cardiac failure, myocardial infarction, tachycardia, ventricular arrhythmia Gastrointestinal Disorders: nausea and vomiting General Disorders and Administration Site Conditions: chest pain, injection site reaction, infusion site pain Immune System Disorders: hypersensitivity Nervous System Disorders: cerebrovascular accident including intracranial hemorrhage, seizure activity including tonic-clonic (grand mal) seizures, loss of consciousness Respiratory, Thoracic and Mediastinal Disorders: bronchospasm, respiratory arrest, throat tightness

adverse reactions

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The following adverse reactions, with an incidence of at least 1%, were reported with adenosine among 1,421 patients in clinical trials. 11% of the adverse reactions occurred several hours after adenosine administration. 8% of the adverse reactions began with adenosine infusion and persisted for up to 24 hours. The most common (incidence ≥ 10%) adverse reactions to adenosine are flushing, chest discomfort, shortness of breath, headache, throat, neck or jaw discomfort, gastrointestinal discomfort, and dizziness (Table 2). Table 2. Adverse Reactions in Clinical Trials (Frequency ≥ 1%) Adverse Reactions Adenosine N=1,421 Flushing 44% Chest discomfort 40% Dyspnea 28% Headache 18% Throat, neck or jaw discomfort 15% Gastrointestinal discomfort 13% Lightheadedness/dizziness 12% Upper extremity discomfort 4% ST segment depression 3% First-degree AV block 3% Second-degree AV block 3% Paresthesia 2% Hypotension 2% Nervousness 2% Arrhythmias 1% Adverse reactions to adenosine of any severity reported in less than 1% of patients include: Body as a Whole: back discomfort, lower extremity discomfort, weakness Cardiovascular System: myocardial infarction, ventricular arrhythmia, third-degree AV block, bradycardia, palpitation, sinus exit block, sinus pause, T-wave changes, hypertension (systolic blood pressure > 200 mm Hg) Respiratory System: cough Central Nervous System: drowsiness, emotional instability, tremors Genital/Urinary System: vaginal pressure, urgency Special Senses: blurred vision, dry mouth, ear discomfort, metallic taste, nasal congestion, scotomas, tongue discomfort

adverse reactions

6.2 Post-Marketing Experience The following adverse reactions have been reported from marketing experience with adenosine. Because these reactions are reported voluntarily from a population of uncertain size, are associated with concomitant diseases and multiple drug therapies and surgical procedures, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiac Disorders: cardiac arrest, atrial fibrillation, cardiac failure, myocardial infarction, tachycardia, ventricular arrhythmia Gastrointestinal Disorders: nausea and vomiting General Disorders and Administration Site Conditions: chest pain, injection site reaction, infusion site pain Immune System Disorders: hypersensitivity Nervous System Disorders: cerebrovascular accident including intracranial hemorrhage, seizure activity including tonic-clonic (grand mal) seizures, loss of consciousness Respiratory, Thoracic and Mediastinal Disorders: bronchospasm, respiratory arrest, throat tightness

adverse reactions table

<table cellspacing="0" cellpadding="0" border="0" width="437"><tbody><tr styleCode="Botrule"><td valign="top" styleCode="Lrule Rrule" align="center"><content styleCode="bold">Adverse Reactions</content> </td><td valign="top" styleCode="Rrule" align="center"><content styleCode="bold">Adenosine</content> <content styleCode="bold">N=1,421</content> </td></tr><tr styleCode="Botrule"><td valign="top" styleCode="Lrule Rrule">Flushing </td><td valign="top" styleCode="Rrule" align="center">44% </td></tr><tr styleCode="Botrule"><td valign="top" styleCode="Lrule Rrule">Chest discomfort </td><td valign="top" styleCode="Rrule" align="center">40% </td></tr><tr styleCode="Botrule"><td valign="top" styleCode="Lrule Rrule">Dyspnea </td><td valign="top" styleCode="Rrule" align="center">28% </td></tr><tr styleCode="Botrule"><td valign="top" styleCode="Lrule Rrule">Headache </td><td valign="top" styleCode="Rrule" align="center">18% </td></tr><tr styleCode="Botrule"><td valign="top" styleCode="Lrule Rrule">Throat, neck or jaw discomfort </td><td valign="top" styleCode="Rrule" align="center">15% </td></tr><tr styleCode="Botrule"><td valign="top" styleCode="Lrule Rrule">Gastrointestinal discomfort </td><td valign="top" styleCode="Rrule" align="center">13% </td></tr><tr styleCode="Botrule"><td valign="top" styleCode="Lrule Rrule">Lightheadedness/dizziness </td><td valign="top" styleCode="Rrule" align="center">12% </td></tr><tr styleCode="Botrule"><td valign="top" styleCode="Lrule Rrule">Upper extremity discomfort </td><td valign="top" styleCode="Rrule" align="center">4% </td></tr><tr styleCode="Botrule"><td valign="top" styleCode="Lrule Rrule">ST segment depression </td><td valign="top" styleCode="Rrule" align="center">3% </td></tr><tr styleCode="Botrule"><td valign="top" styleCode="Lrule Rrule">First-degree AV block </td><td valign="top" styleCode="Rrule" align="center">3% </td></tr><tr styleCode="Botrule"><td valign="top" styleCode="Lrule Rrule">Second-degree AV block </td><td valign="top" styleCode="Rrule" align="center">3% </td></tr><tr styleCode="Botrule"><td valign="top" styleCode="Lrule Rrule">Paresthesia </td><td valign="top" styleCode="Rrule" align="center">2% </td></tr><tr styleCode="Botrule"><td valign="top" styleCode="Lrule Rrule">Hypotension </td><td valign="top" styleCode="Rrule" align="center">2% </td></tr><tr styleCode="Botrule"><td valign="top" styleCode="Lrule Rrule">Nervousness </td><td valign="top" styleCode="Rrule" align="center">2% </td></tr><tr><td valign="top" styleCode="Lrule Rrule">Arrhythmias </td><td valign="top" styleCode="Rrule" align="center">1% </td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.